| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael Won. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. Expert review of neurotherapeutics. vol 13. issue 6. 2014-01-09. PMID:23739003. |
preliminary clinical trials suggest that mtor inhibitors reduce seizures in tuberous sclerosis complex (tsc) patients with intractable epilepsy. |
2014-01-09 |
2023-08-12 |
Not clear |
| Peter T Tsai, Emily Greene-Colozzi, June Goto, Stefanie Anderl, David J Kwiatkowski, Mustafa Sahi. Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice. Behavior genetics. vol 43. issue 1. 2013-12-10. PMID:23229624. |
mammalian target of rapamycin (mtor) signaling has been shown to be deregulated in a number of genetic, neurodevelopmental disorders including tuberous sclerosis complex, neurofibromatosis, fragile x, and rett syndromes. |
2013-12-10 |
2023-08-12 |
mouse |
| Michael Won. Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomedical journal. vol 36. issue 2. 2013-12-10. PMID:23644232. |
hyperactivation of the mtor pathway, leading to increased cell growth and proliferation, has been most convincingly shown to stimulate tumor growth in the brain and other organs in the genetic disorder, tuberous sclerosis complex (tsc). |
2013-12-10 |
2023-08-12 |
Not clear |
| Hui Yang, Xianghui Wang, Yan Zhang, Huanrong Liu, Jiongbo Liao, Kun Shao, Yiwei Chu, Guangwei Li. Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity. Journal of cellular physiology. vol 229. issue 1. 2013-12-09. PMID:23804073. |
in the study of the mtor signaling pathway, tuberous sclerosis complex (tsc) 1/2 complex is identified as a critical regulator of mtor activity. |
2013-12-09 |
2023-08-12 |
Not clear |
| H Peng, J Liu, Q Sun, R Chen, Y Wang, J Duan, C Li, B Li, Y Jing, X Chen, Q Mao, K-F Xu, C L Walker, J Li, J Wang, H Zhan. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development. Oncogene. vol 32. issue 39. 2013-11-15. PMID:23108404. |
the protein complex of tuberous sclerosis complex (tsc)1 and tsc2 tumor suppressors is a key negative regulator of mammalian target of rapamycin (mtor). |
2013-11-15 |
2023-08-12 |
Not clear |
| Marco Cambiaghi, Marco Cursi, Laura Magri, Valerio Castoldi, Giancarlo Comi, Fabio Minicucci, Rossella Galli, Letizia Leocan. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. Neuropharmacology. vol 67. 2013-11-04. PMID:23159330. |
tuberous sclerosis complex (tsc) is a multisystem genetic disorder caused by mutation in either tsc1 or tsc2 genes that leads to the hyper activation of the mtor pathway, a key signalling pathway for synaptic plasticity. |
2013-11-04 |
2023-08-12 |
mouse |
| James L Figarola, Samuel Rahba. Small‑molecule COH-SR4 inhibits adipocyte differentiation via AMPK activation. International journal of molecular medicine. vol 31. issue 5. 2013-10-29. PMID:23525347. |
ampk activation by coh-sr4 also resulted in the phosphorylation of raptor and tuberous sclerosis protein 2 (tsc2), two proteins involved in the mammalian target of rapamycin (mtor) signaling pathways. |
2013-10-29 |
2023-08-12 |
Not clear |
| Juan José García-Peñas, Inmaculada Carreras-Sááe. [Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway]. Revista de neurologia. vol 56 Suppl 1. 2013-10-28. PMID:23446718. |
[autism, epilepsy and tuberous sclerosis complex: a functional model linked to mtor pathway]. |
2013-10-28 |
2023-08-12 |
Not clear |
| Anil J Trindade, Douglas A Medvetz, Nicole A Neuman, Faina Myachina, Jane Yu, Carmen Priolo, Elizabeth P Hensk. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM). PloS one. vol 8. issue 3. 2013-09-30. PMID:23555865. |
lam is caused by mutations in the tuberous sclerosis complex genes (tsc1 or tsc2), resulting in hyperactive mammalian target of rapamycin (mtor) signaling. |
2013-09-30 |
2023-08-12 |
Not clear |
| Hannah Crossland, Abid A Kazi, Charles H Lang, James A Timmons, Philippe Pierre, Daniel J Wilkinson, Kenneth Smith, Nathaniel J Szewczyk, Philip J Atherto. Focal adhesion kinase is required for IGF-I-mediated growth of skeletal muscle cells via a TSC2/mTOR/S6K1-associated pathway. American journal of physiology. Endocrinology and metabolism. vol 305. issue 2. 2013-09-19. PMID:23695213. |
igf-i-induced increases in myotube width (+41 ± 7% vs. non-igf-i-treated) and total protein (+44 ± 6%) were, after 24 h, attenuated in fak-kd cells, whereas mps was suppressed in fak-kd vs. scr after 4 h. these blunted responses were associated with attenuated igf-i-induced fak tyr³⁹⁷ phosphorylation and markedly suppressed phosphorylation of tuberous sclerosis complex 2 (tsc2) and critical downstream mtor signaling (ribosomal s6 kinase, eif4f assembly) in fak shrna cells (all p < 0.05 vs. igf-i-treated scr cells). |
2013-09-19 |
2023-08-12 |
Not clear |
| Dan Ehninge. From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology. vol 68. 2013-09-09. PMID:22626986. |
from genes to cognition in tuberous sclerosis: implications for mtor inhibitor-based treatment approaches. |
2013-09-09 |
2023-08-12 |
human |
| Katarzyna Kotulska, Julita Borkowska, Sergiusz Jozwia. Possible prevention of tuberous sclerosis complex lesions. Pediatrics. vol 132. issue 1. 2013-09-03. PMID:23733802. |
tuberous sclerosis complex (tsc) is a genetic disorder characterized by mammalian target of rapamycin (mtor) activation and growth of benign tumors. |
2013-09-03 |
2023-08-12 |
Not clear |
| Xinxin Xiang, Fang Yuan, Jing Zhao, Ziru Li, Xian Wang, Youfei Guan, Chaoshu Tang, Guang Sun, Yin Li, Weizhen Zhan. Deficiency in pulmonary surfactant proteins in mice with fatty acid binding protein 4-Cre-mediated knockout of the tuberous sclerosis complex 1 gene. Experimental physiology. vol 98. issue 3. 2013-08-22. PMID:23143994. |
tuberous sclerosis complex 1 (tsc1) forms a heterodimmer with tuberous sclerosis complex 2, to inhibit signalling by the mammalian target of rapamycin (mtor) complex 1 (mtorc1). |
2013-08-22 |
2023-08-12 |
mouse |
| Bo Zhang, Sharon S McDaniel, Nicholas R Rensing, Michael Won. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PloS one. vol 8. issue 2. 2013-08-06. PMID:23437388. |
vigabatrin inhibits seizures and mtor pathway activation in a mouse model of tuberous sclerosis complex. |
2013-08-06 |
2023-08-12 |
mouse |
| Michael Won. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations. Experimental neurology. vol 244. 2013-08-02. PMID:22015915. |
in animal models and human studies of fcd and the related disease of tuberous sclerosis complex (tsc), the mammalian target of rapamycin (mtor) pathway has been implicated in mediating cellular and molecular changes leading to the formation of the cortical malformations and the expression of epilepsy. |
2013-08-02 |
2023-08-12 |
human |
| Zhao Zhong Chong, Yan Chen Shang, Shaohui Wang, Kenneth Maies. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Progress in neurobiology. vol 99. issue 2. 2013-07-22. PMID:22980037. |
mtor signaling is dependent upon the mtorc1 and mtorc2 complexes that are composed of mtor and several regulatory proteins including the tuberous sclerosis complex (tsc1, hamartin/tsc2, tuberin). |
2013-07-22 |
2023-08-12 |
Not clear |
| John J Bissler, J Christopher Kingswood, Elżbieta Radzikowska, Bernard A Zonnenberg, Michael Frost, Elena Belousova, Matthias Sauter, Norio Nonomura, Susanne Brakemeier, Petrus J de Vries, Vicky H Whittemore, David Chen, Tarek Sahmoud, Gaurav Shah, Jeremie Lincy, David Lebwohl, Klemens Budd. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England). vol 381. issue 9869. 2013-07-01. PMID:23312829. |
angiomyolipomas are slow-growing tumours associated with constitutive activation of mammalian target of rapamycin (mtor), and are common in patients with tuberous sclerosis complex and sporadic lymphangioleiomyomatosis. |
2013-07-01 |
2023-08-12 |
Not clear |
| Kenneth Maiese, Zhao Zhong Chong, Yan Chen Shang, Shaohui Wan. mTOR: on target for novel therapeutic strategies in the nervous system. Trends in molecular medicine. vol 19. issue 1. 2013-06-11. PMID:23265840. |
recent studies highlight the importance of both traditional and newly recognized interactors of mtor, such as p70s6k, 4ebp1, gsk-3β, redd1/rtp801, tsc1/tsc2, growth factors, wingless, and forkhead transcription factors, that influence alzheimer's disease, parkinson's disease, huntington's disease, tuberous sclerosis, and epilepsy. |
2013-06-11 |
2023-08-12 |
Not clear |
| Paolo Curatolo, Romina Moaver. mTOR Inhibitors in Tuberous Sclerosis Complex. Current neuropharmacology. vol 10. issue 4. 2013-06-05. PMID:23730262. |
mtor inhibitors in tuberous sclerosis complex. |
2013-06-05 |
2023-08-12 |
Not clear |
| B Duchemann, B Duchemain, S Wong, V Baruch-Hennequin, S Rivera, L Quero, C Hennequi. [Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. vol 17. issue 1. 2013-04-18. PMID:23270679. |
tuberous sclerosis is characterized by a loss of the tsc2 function, with a permanent activation of the mtor pathway. |
2013-04-18 |
2023-08-12 |
Not clear |